TAYSHA GENE THERAPIES INC (TSHA)
US8776191061 - Common Stock
We assign a fundamental rating of 2 out of 10 to TSHA. TSHA was compared to 565 industry peers in the Biotechnology industry. TSHA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TSHA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year TSHA was profitable.
TSHA had a negative operating cash flow in the past year.
In the past 5 years TSHA always reported negative net income.
In the past 5 years TSHA always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of TSHA (-57.06%) is comparable to the rest of the industry.
TSHA has a Return On Equity (-105.02%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.06% | ||
| ROE | -105.02% | ||
| ROIC | N/A |
ROA(3y)-92.53%
ROA(5y)N/A
ROE(3y)-6259.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for TSHA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TSHA has been increased compared to 1 year ago.
TSHA has a better debt/assets ratio than last year.
2.2 Solvency
TSHA has an Altman-Z score of -2.05. This is a bad value and indicates that TSHA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.05, TSHA is in line with its industry, outperforming 50.62% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that TSHA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.35, TSHA is not doing good in the industry: 71.66% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.05 |
ROIC/WACCN/A
WACC10.6%
2.3 Liquidity
TSHA has a Current Ratio of 5.22. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
TSHA has a Current ratio of 5.22. This is comparable to the rest of the industry: TSHA outperforms 56.33% of its industry peers.
A Quick Ratio of 5.22 indicates that TSHA has no problem at all paying its short term obligations.
TSHA's Quick ratio of 5.22 is in line compared to the rest of the industry. TSHA outperforms 57.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.22 | ||
| Quick Ratio | 5.22 |
3. Growth
3.1 Past
TSHA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 136.59%, which is quite impressive.
Looking at the last year, TSHA shows a very strong growth in Revenue. The Revenue has grown by 34.00%.
EPS 1Y (TTM)136.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.32%
Revenue 1Y (TTM)34%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-53.57%
3.2 Future
Based on estimates for the next years, TSHA will show a very negative growth in Earnings Per Share. The EPS will decrease by -34.21% on average per year.
The Revenue is expected to grow by 60.28% on average over the next years. This is a very strong growth
EPS Next Y-402.55%
EPS Next 2Y-129.95%
EPS Next 3Y-76.17%
EPS Next 5Y-34.21%
Revenue Next Year-42.23%
Revenue Next 2Y-39.89%
Revenue Next 3Y-28.99%
Revenue Next 5Y60.28%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 3.98 indicates a rather cheap valuation of TSHA.
Based on the Price/Earnings ratio, TSHA is valued cheaper than 99.64% of the companies in the same industry.
TSHA's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.12.
TSHA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.98 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TSHA's earnings are expected to decrease with -76.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-129.95%
EPS Next 3Y-76.17%
5. Dividend
5.1 Amount
TSHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TAYSHA GENE THERAPIES INC
NASDAQ:TSHA (11/12/2024, 8:00:01 PM)
After market: 2.4499 +0.06 (+2.51%)2.39
+0.76 (+46.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap489.81M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.98 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -57.06% | ||
| ROE | -105.02% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.22 | ||
| Quick Ratio | 5.22 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)136.59%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-402.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)34%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y